The Canadian COVID-19 Prospective Cohort Study (CANCOV) is the first Canadian study to provide a comprehensive evaluation of early to 1-year outcomes in patients with COVID-19 and their family caregivers.
We are a consortium of interdisciplinary investigators and clinicians leading multiple COVID19 studies across Canada. Our research ranges from genomics and epigenomics to antibody testing and immune analyses.
We plan to recruit 2000 (1000 non-hospitalized and 1000 hospitalized) patients and 500 family caregivers from the four hardest-hit provinces in Canada: Quebec, Ontario, Alberta and British Columbia.
Patients who are critically ill and require admission to an intensive care unit (ICU) or mechanical ventilation.
Patients who are sick enough to require admission to acute care hospitals.
Patients who are diagnosed at COVID-19 assessment centres, emergency rooms and clinics, and told to isolate at home.
OUR CO-LEAD INVESTIGATORS
Dr. Angela Cheung
Dr. Angela M. Cheung is a Professor of Medicine and the KY and Betty Ho Chair of Integrative Medicine at the University of Toronto. She is an Internal Medicine specialist and senior scientist at the University Health Network and holds a Tier 1 Canada Research Chair in Musculoskeletal and Postmenopausal Health. She obtained her MD from Johns Hopkins University and completed her training in General Internal Medicine at the University of Toronto and Beth Israel Deaconess Hospital in Boston, and her Ph.D. from Harvard University.
Dr. Margaret Herridge
Dr. Margaret S. Herridge is a Professor of Medicine, Critical Care and Pulmonary Medicine at the University Health Network; Senior Scientist in the Toronto General Research Institute; Director of Research for the Interdepartmental Division of Critical Care Medicine, University of Toronto. She obtained her MD from Queen’s University at Kingston, completed her clinical training in Respiratory and Critical Care Medicine at the University of Toronto and obtained her MPH at the Harvard School of Public Health.